1-(acetyloxy)indolizine | 949101-41-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-(acetyloxy)indolizine
• 英文别名: Indolizin-1-yl acetate
• CAS: 949101-41-1
• 化学式: C₁₀H₉NO₂
• 分子量: 175.187
• InChiKey: DNSNHOUTDMDJLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(acetyloxy)indolizine 在 copper diacetate 、 palladium diacetate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以66%的产率得到[3-(1-Acetyloxyindolizin-3-yl)indolizin-1-yl] acetate
  参考文献：
  名称：

  Synthesis of Biindolizines through Highly Regioselective Palladium-Catalyzed C−H Functionalization

  摘要：

  Biindolizines were synthesized under mild conditions with excellent regioselectivity in high yields through palladium-catalyzed C-H functionalization of indolizines. Synthesis of a macrocyclic compound was also achieved via intramolecular double C-H functionalization.

  DOI：

  10.1021/jo802227u
• 作为产物：
  描述：

  acetic acid 1-(pyridin-2-yl)-3-trimethylsilyl-prop-2-ynyl ester 在 copper(l) iodide 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 16.0h， 以68%的产率得到1-(acetyloxy)indolizine
  参考文献：
  名称：

  Highly Efficient Synthesis of Functionalized Indolizines and Indolizinones by Copper-Catalyzed Cycloisomerizations of Propargylic Pyridines

  摘要：

  [GRAPHICS]The copper-catalyzed cycloisomerizations of 2-pyridyl-substituted propargylic acetates and its derivatives are described, which offer an efficient route to C-1 oxygenated indolizines with a wide range of substituents under mild reaction conditions. The presented method could be readily applied to the synthesis of indolizinones through a cyclization/1,2-migration of tertiary propargylic alcohols.

  DOI：

  10.1021/jo070983j

文献信息

• Multisubstituted N-fused heterocycles via transition metal-catalyzed cycloisomerization protocols
  作者：Ilya V. Seregin、Alex W. Schammel、Vladimir Gevorgyan

  DOI：10.1016/j.tet.2008.04.023

  日期：2008.7

  multisubstituted N-fused heterocycles have been developed. It was demonstrated that 1,3-disubstituted N-fused heterocycles, including indolizines, pyrroloquinoxalines, and pyrrolothiazoles can easily be synthesized via an exceptionally mild and efficient method involving a novel silver-catalyzed cycloizomerization of propargyl-containing heterocycles. Alternatively, 1,2-disubstituted heterocycles can be accessed

  已经开发了两种用于组装多取代 N-稠合杂环的互补方案。结果表明，1,3-二取代的 N-稠合杂环，包括中氮茚、吡咯并喹喔啉和吡咯并噻唑，可以通过一种极其温和且有效的方法轻松合成，该方法涉及新型银催化含炔丙基杂环的环化聚合。或者，可以通过涉及炔烃-亚乙烯基异构化以及伴随的氢、甲硅烷基、甲锡烷基或甲锗烷基基团的1,2-位移的新型级联转化来获得1,2-二取代的杂环。这种温和而简单的方法可以选择性且高效地合成中氮茚、吡咯并异喹啉、吡咯并喹喔啉、吡咯并吡嗪和吡咯并噻唑。
• [EN] INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE AVEC UNE AFFINITÉ POUR LE RÉCEPTEUR CRTH2 POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2009044134A1

  公开（公告）日：2009-04-09

  Compounds of formula (I) are ligands of the CRTH2 receptor useful in the treatment of, for example, inflammatory respiratory diseases: R1 is fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; X is -CH2-, or - S(O)n-; Ar1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C1C3alkyl) or C1-C3alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR3R4-, -C(O)-, -O-, -S(O)n- or -NR3-; R3 and R4 independently represent hydrogen or C1C3alkyl; Ar2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O)nR5, -S(O)2NR6R7, -NR6S(O)2R5 -NR6R7, -NR6COR5, -CONR6R7, - COR5, -OR6, C1C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R5 is C1C6alkyl or C3-C7cycloalkyl, optionally substituted by one or more fluoro atoms; R6 and R7 independently represent hydrogen, C1C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.

  式(I)的化合物是CRTH2受体的配体，在治疗例如炎症性呼吸道疾病方面有用：R1是氟、氯、CN或CF3；R2是氢、氟或氯；X是-CH2-或-S(O)n-；Ar1是苯基或5-或6-成员杂环烷基，其中苯基或杂环烷基环可选择地被氟、氯、CN、-O(C1C3烷基)或C1-C3烷基中的一种取代基取代，后两个基可选择地被一个或多个氟原子取代；Y是-CR3R4-、-C(O)-、-O-、-S(O)n-或-NR3-；R3和R4独立地代表氢或C1C3烷基；Ar2是苯基或5-或6-成员杂环烷基，其中苯基或杂环烷基环可选择地被一个或多个取代基独立地选自卤素、-CN、-S(O)nR5、-S(O)2NR6R7、-NR6S(O)2R5 -NR6R7、-NR6COR5、-CONR6R7、-COR5、-OR6、C1C6烷基或C3-C7环烷基取代，后两个基可选择地被一个或多个氟原子取代；R5是C1C6烷基或C3-C7环烷基，可选择地被一个或多个氟原子取代；R6和R7独立地代表氢、C1C6烷基或C3-C7环烷基，后两个基可选择地被一个或多个氟原子取代；n是O、1或2。
• [EN] INDOLIZINE DERIVATIVES WITH CRTH2 RECEPTOR AFFINITY FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DÉRIVÉS D'INDOLIZINE AVEC UNE AFFINITÉ POUR LE RÉCEPTEUR CRTH2 DESTINÉS AU TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2009044147A1

  公开（公告）日：2009-04-09

  Compounds of formula (I) are ligands of the CRTH2 receptor, useful in the treatment of, for example, inflammatory respiratory disease: R1 is fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; X is -CH2-, or - S(O)n-; Ar1 is phenyl or 5- or 6-membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted with one substituent selected from fluoro, chloro, CN, -O(C1-C3alkyi) or C1-C3alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; Y is -CR3R4-, -C(O)-, -O-, -S(O)2- or -NR3-; R3 and R4 independently represent hydrogen or C1-C3alkyl; Ar2 is phenyl or 5- or 6- membered heteroaryl, wherein the phenyl or heteroaryl rings are optionally substituted by one or more substituents independently selected from halogen, - CN, -S(O)nR5, -S(O)2NR6R7, -NR6S(O)2R5 -NR6R7, -NR6COR5, -CONR6R7, -COR5, -OR6, C1- C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; R5 is C1-C6alkyl or C3-C7cycloalkyl, optionally substituted by one or more fluoro atoms; R6 and R7 independently represent hydrogen, C1-C6alkyl or C3-C7cycloalkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and n is O, 1 or 2.

  化合物的结构式（I）是CRTH2受体的配体，在治疗例如炎症性呼吸道疾病方面很有用：R1是氟、氯、CN或CF3；R2是氢、氟或氯；X是-CH2-或-S(O)n-；Ar1是苯基或5-或6-成员杂环基，其中苯基或杂环基环可以选择性地用来自氟、氯、CN、-O（C1-C3烷基）或C1-C3烷基的一个取代基取代，后两个基可以选择性地用一个或多个氟原子取代；Y是-CR3R4-，-C(O)-，-O-，-S(O)2-或-NR3-；R3和R4独立地代表氢或C1-C3烷基；Ar2是苯基或5-或6-成员杂环基，其中苯基或杂环基环可以选择性地用一个或多个取代基独立地选自卤素、-CN、-S(O)nR5、-S(O)2NR6R7、-NR6S(O)2R5、-NR6R7、-NR6COR5、-CONR6R7、-COR5、-OR6、C1-C6烷基或C3-C7环烷基取代，后两个基可以选择性地用一个或多个氟原子取代；R5是C1-C6烷基或C3-C7环烷基，可以选择性地用一个或多个氟原子取代；R6和R7独立地代表氢、C1-C6烷基或C3-C7环烷基，后两个基可以选择性地用一个或多个氟原子取代；n是O、1或2。
• Desulfitative palladium-catalyzed direct C-3 arylation of indolizines with arylsulfonyl chlorides
  作者：Wei Zhang、Fang Liu、Baoli Zhao

  DOI：10.1002/aoc.3326

  日期：2015.8

  Pd‐catalyzed desulfitative approach to C‐3 arylation of indolizine derivatives has been developed, and the protocol uses readily available arylsulfonyl chlorides as the arylation reagent under nitrogen. This transformation was performed in a mixed solvent of 1‐methyl‐2‐pyrrolidone and dimethoxyethane using simple triphenylphosphine as a ligand, which provides a new method for the C‐3 arylation of indolizines

  已经开发了一种高效的Pd催化的吲哚嗪衍生物C-3芳基化脱硫方法，并且该方案使用易于获得的芳基磺酰氯作为氮气氛下的芳基化试剂。这种转化是在1-甲基-2-吡咯烷酮和二甲氧基乙烷的混合溶剂中使用简单的三苯基膦作为配体进行的，这为吲哚嗪的C-3芳基化提供了一种新方法。版权所有©2015 John Wiley＆Sons，Ltd.
• [EN] INDOLES AND THEIR THERAPEUTIC USE<br/>[FR] INDOLES ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2009077728A1

  公开（公告）日：2009-06-25

  Compound of formula (I) are are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is -SO2- or *-SO2NR3- wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, C1C8alkyl or C3-C7cycloalkyl; Ar1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3- C7cycloalkyl, -O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3- C3- C7cycloalkyl, -O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.

  式(I)的化合物是CRTH2受体的配体，尤其适用于治疗炎症性疾病。其中，X为-SO2-或*-SO2NR3-，其中带有星号的键连接到Ar1；R1为氢、氟、氯、氰基或三氟甲基；R2为氢、氟或氯；R3为氢、C1-C8烷基或C3-C7环烷基；Ar1为苯基或选自呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基，其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代，后两个基团可任选地被一个或多个氟原子取代；Ar2为苯基或选自吡咯基、呋喃基、噻吩基、噁唑基、噻唑基、咪唑基、吡唑基、异噁唑基、异噻唑基、吡啶基、吡嗪基、嘧啶基和哒嗪基的5或6元杂芳基，其中苯基或杂芳基可任选地被一个或多个独立选自氟、氯、氰基、C3-C7环烷基、-O(C1-C4烷基)或C1-C6烷基的取代基取代，后两个基团可任选地被一个或多个氟原子取代。